MX336381B - Boronatos como inhibidores de arginasa. - Google Patents

Boronatos como inhibidores de arginasa.

Info

Publication number
MX336381B
MX336381B MX2013004491A MX2013004491A MX336381B MX 336381 B MX336381 B MX 336381B MX 2013004491 A MX2013004491 A MX 2013004491A MX 2013004491 A MX2013004491 A MX 2013004491A MX 336381 B MX336381 B MX 336381B
Authority
MX
Mexico
Prior art keywords
boronates
arginase inhibitors
arginase
activity
compounds
Prior art date
Application number
MX2013004491A
Other languages
English (en)
Other versions
MX2013004491A (es
Inventor
Michael Van Zandt
Erik Jagdmann Gunnar Jr
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Publication of MX2013004491A publication Critical patent/MX2013004491A/es
Publication of MX336381B publication Critical patent/MX336381B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Los compuestos de acuerdo con la Fórmula I son inhibidores potentes de la actividad de arginasa I y II: (I) en donde R1, R2, R3, R4, D, W, X, Y, y Z se definen en la especificación. La invención también proporciona las composiciones farmacéuticas de los compuestos y los métodos de su uso en el tratamiento o prevención de una enfermedad o una condición asociada con la actividad de arginasa.
MX2013004491A 2010-10-26 2011-10-19 Boronatos como inhibidores de arginasa. MX336381B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40676010P 2010-10-26 2010-10-26
PCT/US2011/056844 WO2012058065A1 (en) 2010-10-26 2011-10-19 Boronates as arginase inhibitors

Publications (2)

Publication Number Publication Date
MX2013004491A MX2013004491A (es) 2013-11-04
MX336381B true MX336381B (es) 2016-01-18

Family

ID=44913403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004491A MX336381B (es) 2010-10-26 2011-10-19 Boronatos como inhibidores de arginasa.

Country Status (19)

Country Link
US (5) US9233985B2 (es)
EP (3) EP2632927B1 (es)
JP (1) JP5909239B2 (es)
CN (2) CN103249737B (es)
AU (1) AU2011320732B2 (es)
BR (1) BR112013010099B1 (es)
CA (1) CA2815536C (es)
DK (1) DK2632927T3 (es)
ES (2) ES2568680T3 (es)
HK (2) HK1223104A1 (es)
HR (1) HRP20160305T1 (es)
HU (1) HUE027317T2 (es)
IL (1) IL225926A (es)
MX (1) MX336381B (es)
PL (1) PL2632927T3 (es)
RS (1) RS54750B1 (es)
SI (1) SI2632927T1 (es)
SM (1) SMT201600141B (es)
WO (1) WO2012058065A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162535A (en) 2010-04-22 2017-06-15 Mars Inc Inhibitors of arginase and their therapeutic applications
PT2603514T (pt) 2010-08-10 2018-11-09 Rempex Pharmaceuticals Inc Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
AU2013249790B2 (en) * 2012-04-18 2018-01-25 Mars, Incorporated Ring constrained analogs as Arginase inhibitors
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2944903A1 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
LT3604316T (lt) 2014-05-05 2024-02-26 Melinta Therapeutics, Inc. Boronato druskų sintezė
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016003929A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
SG10202110144TA (en) 2015-06-23 2021-10-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
MX2018003898A (es) 2015-10-01 2018-12-17 Potenza Therapeutics Inc Proteínas de unión al antígeno anti-tigit y métodos para usarlas.
RS60695B1 (sr) * 2015-10-30 2020-09-30 Calithera Biosciences Inc Supstance i postupci za inhibiranje aktivnosti arginaze
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
DK3478693T3 (da) 2016-06-30 2021-09-20 Qpex Biopharma Inc Boronsyrederivater og terapeutiske anvendelser deraf
JP2020502259A (ja) 2016-11-08 2020-01-23 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ阻害剤併用療法
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
MA48626A (fr) 2017-05-12 2020-03-18 Calithera Biosciences Inc Procédé de préparation de (3r,4s)-3-acétamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
JOP20200197A1 (ar) 2018-02-17 2020-08-16 Astrazeneca Ab مثبطات أرجيناز وطرق لاستخدامها
CN111818928A (zh) * 2018-03-05 2020-10-23 艾库斯生物科学有限公司 精氨酸酶抑制剂
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
CN111770756B (zh) * 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
AR117102A1 (es) 2018-11-16 2021-07-14 Arcus Biosciences Inc Inhibidores de arg1 y/o arg2
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020131598A1 (en) * 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN113614095A (zh) * 2019-02-06 2021-11-05 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
PL3921033T3 (pl) * 2019-02-08 2024-01-15 Astrazeneca Ab Inhibitory arginazy i sposoby ich zastosowania
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme Llc ARGINASE INHIBITORS AND METHODS OF USE
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2023283332A1 (en) * 2021-07-07 2023-01-12 Emory University Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions
WO2023191116A2 (en) 2022-01-21 2023-10-05 Opiyo Sammy Oyoo Improved suramin methods and compositions
WO2023178285A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009890A (en) 1911-02-09 1911-11-28 Michael F Brauer Dumping attachment for headers.
US1006597A (en) 1911-05-26 1911-10-24 Rail Joint Co Insulated rail-joint.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
KR100507984B1 (ko) 1997-07-29 2005-08-17 알콘 래보레이토리스, 인코퍼레이티드 갈락토만난 중합체 및 붕산염을 함유하는 안과용 조성물
CA2305703A1 (en) * 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
JP2004502948A (ja) 2000-07-06 2004-01-29 ファル　ダイアグノスティクス アルギニン化合物の検出のための方法及びキット
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
WO2008061612A1 (en) 2006-11-21 2008-05-29 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
EP2172655B1 (en) 2007-07-12 2018-10-24 Sanyo Denki Co., Ltd. Dual reversal-rotating type axial blower
CA2702475A1 (en) 2007-10-12 2009-04-23 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of ophthalmic conditions
EP2282739A2 (en) 2008-05-05 2011-02-16 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
TR201910726T4 (tr) * 2009-01-26 2019-08-21 Astrazeneca Uk Ltd Arginaz inhibitörleri ve kullanım yöntemleri.
MY162535A (en) 2010-04-22 2017-06-15 Mars Inc Inhibitors of arginase and their therapeutic applications
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
WO2012091757A1 (en) 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2013059587A1 (en) 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
AU2013249790B2 (en) 2012-04-18 2018-01-25 Mars, Incorporated Ring constrained analogs as Arginase inhibitors
KR20150080592A (ko) 2012-11-02 2015-07-09 파마시클릭스, 인코포레이티드 Tec 패밀리 키나제 억제제 애쥬번트 요법
EA029126B1 (ru) 2013-07-01 2018-02-28 Бристол-Майерс Сквибб Компани Ингибиторы ido
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 ***的增效药物复合物及其制备方法
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2016153078A1 (en) 2015-03-20 2016-09-29 Opiyo Sammy Oyoo Use of suramin and arginase inhibitors in malignant neoplasia
SG10202110144TA (en) 2015-06-23 2021-10-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
RS60695B1 (sr) 2015-10-30 2020-09-30 Calithera Biosciences Inc Supstance i postupci za inhibiranje aktivnosti arginaze
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
MA48626A (fr) 2017-05-12 2020-03-18 Calithera Biosciences Inc Procédé de préparation de (3r,4s)-3-acétamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

Also Published As

Publication number Publication date
AU2011320732B2 (en) 2018-07-05
CN103249737A (zh) 2013-08-14
HRP20160305T1 (hr) 2016-07-01
SMT201600141B (it) 2016-07-01
CN103249737B (zh) 2016-06-08
ES2794006T3 (es) 2020-11-17
DK2632927T3 (en) 2016-04-11
US9233985B2 (en) 2016-01-12
US9440995B2 (en) 2016-09-13
JP2013542223A (ja) 2013-11-21
PL2632927T3 (pl) 2016-09-30
CN106008569B (zh) 2020-04-03
CN106008569A (zh) 2016-10-12
HK1223104A1 (zh) 2017-07-21
EP3034509B1 (en) 2020-04-22
AU2011320732A1 (en) 2013-11-21
US20170000808A1 (en) 2017-01-05
JP5909239B2 (ja) 2016-04-26
BR112013010099A2 (pt) 2016-09-06
CN106008569B9 (zh) 2020-05-22
US10603330B2 (en) 2020-03-31
BR112013010099B1 (pt) 2021-08-10
EP3034509A1 (en) 2016-06-22
HUE027317T2 (en) 2016-10-28
CA2815536A1 (en) 2012-05-03
EP3719024A1 (en) 2020-10-07
IL225926A (en) 2016-09-29
US11389464B2 (en) 2022-07-19
US20200246362A1 (en) 2020-08-06
ES2568680T3 (es) 2016-05-03
EP2632927A1 (en) 2013-09-04
WO2012058065A1 (en) 2012-05-03
US20190054101A1 (en) 2019-02-21
CA2815536C (en) 2019-10-01
HK1225390A1 (zh) 2017-09-08
US20150191492A1 (en) 2015-07-09
MX2013004491A (es) 2013-11-04
US20120129806A1 (en) 2012-05-24
RS54750B1 (sr) 2016-10-31
EP2632927B1 (en) 2016-02-10
US10098902B2 (en) 2018-10-16
SI2632927T1 (sl) 2016-08-31
IL225926A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
MX336381B (es) Boronatos como inhibidores de arginasa.
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
PH12015500260A1 (en) Neprilysin inhibitors
MA33939B1 (fr) 5-alcynyl-pyrimidines
MY165087A (en) Neprilysin inhibitors
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
MX354476B (es) Inhibidores de neprilisina.
MX2013008212A (es) Derivados de 7-azaindol.
MY170935A (en) Neprilysin inhibitors
EA201201648A1 (ru) Стимуляторы sgc
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12015501038A1 (en) Inhibitors of iap
MX2014002682A (es) Modulares de la fosfodiesterasa 10 (pde 10).
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MX2013002398A (es) Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments